After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.

NeuroSolve is a four-year project funded by the European Commission and EDCTP3, started on May 1, 2023. The African Institutions involved are: University of Dar es Salaam (Tanzania), Sokoine University of Agriculture (Tanzania), University of Zambia (Zambia); the European Institutions are: Universiteit Ghent (Belgium) and R-Evolution Worldwide Srl – Impresa Sociale (Italy), that is also the project Coordinator. NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.

Potrebbe essere un'immagine raffigurante testo

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

INTEGRA-WINGS proposal submitted to EDCTP3 call on HIV co-morbidities in sub-Saharan Africa

Across sub-Saharan Africa, women living with HIV face a disproportionate burden of co-morbidities affecting sexual and reproductive health, particularly female genital schistosomiasis (FGS) and persistent human papillomavirus (HPV) infection. These

Read More

NeuroSolve Project Kick-off Meeting in Lusaka, Zambia

The NeuroSolve consortium held its Project Kick-off Meeting on the 4th December 2023 in Lusaka (Zambia). NeuroSolve is a four-year project funded by EDCTP3, lead by an African-European research consortium

Read More

PRECISION-asympTB – Proposal submitted to EDCTP3 call for innovative TB treatment research in sub-Saharan Africa

PRECISION-asympTB was submitted under the EDCTP3 2026 Call on Tuberculosis.  Despite decades of global efforts, TB remains one of the leading infectious causes of death worldwide. One of the greatest challenges today

Read More